Telix Pharmaceuticals Ltd ADR (TLX): Next-Year EPS Estimate 28.73%

As of 2026-08-20, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 28.73%. Featured in our EPS revision report on 2026-04-13.

Latest revision: 154.21% → 28.73%
Revised on 2026-08-20

On 2026-08-20, analyst consensus for TLX's next-year EPS growth shifted from 154.21% to 28.73% — a negative change of 125.48 percentage points. Current-year growth is projected at 373.04%.

What's Driving This

Despite a sharp downward revision to next-year EPS growth estimates on 2026-08-20, the stock has risen on specific corporate catalysts: the strategic radiopharma collaboration with Regeneron and the FDA's acceptance of the NDA for TLX101-Px (Pixclara). These headline events, rather than any earnings upgrade, appear to

Generated 2026-08-25 from news as of 2026-08-20

Current Snapshot

Sector
Healthcare
Industry
Biotechnology
EPS growth next year
28.73%
EPS growth this year
373.04%
EPS next quarter (est)
$0.00
Last price
$12.36

EPS Revision History

154.2%28.7%07-2107-2808-0508-1208-20
Next-year EPS growth estimate · latest 30 days · 27 observations
434.2%401.8%07-2107-2808-0508-1208-20
Combined EPS growth (this year + next year) · latest 30 days · 27 observations
DateEPS Next YEPS This YNext Q (est)Price
2026-08-2028.73%373.04%$0.00$12.36
2026-08-19154.21%274.06%N/A$12.12
2026-08-18154.21%274.06%N/A$11.88
2026-08-17154.21%274.06%N/A$11.73
2026-08-16154.21%274.06%N/A$11.82
2026-08-14154.21%274.06%N/A$11.82
2026-08-13154.21%274.06%N/A$12.33
2026-08-12154.21%274.06%N/A$11.97
2026-08-11154.21%274.06%N/A$12.00
2026-08-10154.21%274.06%N/A$11.79
2026-08-09154.21%274.06%N/A$11.52
2026-08-07154.21%274.06%N/A$11.52
2026-08-06154.21%274.06%N/A$10.64
2026-08-05154.21%274.06%N/A$10.42
2026-08-04154.21%274.06%N/A$10.29
2026-08-03154.21%274.06%N/A$10.02
2026-08-02154.21%274.06%N/A$9.89
2026-07-31154.21%274.06%N/A$9.89
2026-07-30154.21%274.06%N/A$10.06
2026-07-29154.21%274.06%N/A$10.10
2026-07-28154.21%274.06%N/A$10.19
2026-07-27119.25%301.82%N/A$9.98
2026-07-26119.25%301.82%N/A$10.22
2026-07-24119.25%301.82%N/A$10.22
2026-07-23117.86%304.18%N/A$10.51
2026-07-22117.86%304.18%N/A$10.32
2026-07-21121.88%312.31%N/A$10.92
2026-07-20136.73%313.86%N/A$10.51
2026-07-19173.98%268.67%N/A$10.46
2026-07-17173.98%268.67%N/A$10.46

Reports Featuring TLX

Recent News

Screen Performance

Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.

Median return since detection
+3.1%
% of tickers in the green
56%
Median return on winners
+19.9%
Large revisions captured
1606

Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.

Also Tracked by Our Screen

Frequently Asked Questions

What is Telix Pharmaceuticals Ltd ADR's next-year EPS growth estimate?

As of 2026-08-20, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 28.73%, based on analyst consensus.

When was the latest EPS estimate revision for TLX?

The most recent revision occurred on 2026-08-20, when analysts adjusted the next-year EPS growth estimate from 154.21% to 28.73%.

What sector and industry does Telix Pharmaceuticals Ltd ADR belong to?

Telix Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.

How often is this EPS estimate data updated?

EPS revision data is refreshed daily from analyst consensus estimates. TLX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.

EPS revision data sourced from analyst consensus estimates, refreshed daily. Telix Pharmaceuticals Ltd ADR (TLX) appears here because it was detected by our daily top-EPS-revision-performer screen.